Literature DB >> 30019221

Minimally invasive surgery techniques in pelvic exenteration: a systematic and meta-analysis review.

.   

Abstract

BACKGROUND: Pelvic exenteration is potentially curative for locally advanced and recurrent pelvic cancers. Evolving technology has facilitated the use of minimally invasive surgical (MIS) techniques in selected cases. We aimed to compare outcomes between open and MIS pelvic exenteration.
METHODS: A review of comparative studies was performed. Firstly, we evaluated the differences in surgical techniques with respect to operative time, blood loss, and margin status. Secondly, we assessed differences in 30-day morbidity and mortality rates, and length of hospital stay.
RESULTS: Four studies that directly compared open and MIS exenteration were included. Analysis was performed on 170 patients; 78.1% (n = 133) had open pelvic exenteration, while 21.8% (n = 37) had a MIS exenteration. The median age for open exenteration was 57.7 years versus 63 years for MIS exenteration. Even though the operative time for MIS exenteration was 83 min longer (p < 0.001), it was associated with a median of 1,750mls less blood loss. The morbidity rate for MIS exenterative group was 56.7% (n = 21/37) versus 88.5% (n = 85/96) in the open exenteration group, with pooled analysis observing a 1.17 relative risk increase in 30-day morbidity (p = 0.172) in the open exenteration group. In addition, the MIS cohort had a 6-day shorter length of hospital stay (p = 0.04).
CONCLUSION: MIS exenteration can be performed in highly selective cases, where there is favourable patient anatomy and tumour characteristics. When feasible, it is associated with reduced intra-operative blood loss, shorter length of hospital stay, and reduced morbidity.

Entities:  

Keywords:  Laparoscopic surgery; Minimally invasive surgery; Pelvic exenteration; Robotic surgery; Surgical complications; Surgical outcomes

Mesh:

Year:  2018        PMID: 30019221     DOI: 10.1007/s00464-018-6299-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  36 in total

Review 1.  Robotic surgery for early stage cervical cancer: Evolution and current trends.

Authors:  Erin E Medlin; David M Kushner; Lisa Barroilhet
Journal:  J Surg Oncol       Date:  2015-12       Impact factor: 3.454

2.  Pelvic exenteration for advanced pelvic malignancies.

Authors:  H H Yu; C H Leong; G B Ong
Journal:  Aust N Z J Surg       Date:  1976-08

3.  Interpreting estimates of treatment effects: implications for managed care.

Authors:  Stephen V Faraone
Journal:  P T       Date:  2008-12

4.  Outcome of total pelvic exenteration for primary rectal cancer.

Authors:  Hideyuki Ike; Hiroshi Shimada; Shigeki Yamaguchi; Yasushi Ichikawa; Shouichi Fujii; Shigeo Ohki
Journal:  Dis Colon Rectum       Date:  2003-04       Impact factor: 4.585

5.  Initial experience of robotic anterior pelvic exenteration at a single institute.

Authors:  Shailesh Puntambekar; Akhil Lawande; Riddhi Desai; Seema Puntambekar; Geetanjali A Joshi; Saurabh N Joshi
Journal:  Int J Gynaecol Obstet       Date:  2014-04-02       Impact factor: 3.561

6.  T4 colorectal cancer: is laparoscopic resection contraindicated?

Authors:  F Bretagnol; A Dedieu; M Zappa; N Guedj; M Ferron; Y Panis
Journal:  Colorectal Dis       Date:  2011-02       Impact factor: 3.788

Review 7.  Role of Minimally Invasive Surgery in the Reoperative Abdomen or Pelvis.

Authors:  Amanda Feigel; Patricia Sylla
Journal:  Clin Colon Rectal Surg       Date:  2016-06

8.  Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement.

Authors:  Kirk K S Austin; Michael J Solomon
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

Review 9.  Review of 500 single incision laparoscopic colorectal surgery cases - Lessons learned.

Authors:  Deborah S Keller; Juan R Flores-Gonzalez; Sergio Ibarra; Eric M Haas
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Total pelvic exenteration for primary and recurrent malignancies.

Authors:  F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

View more
  6 in total

1.  Minimally invasive versus open pelvic exenterations for rectal cancer: a comparative analysis of perioperative and 3-year oncological outcomes.

Authors:  M Kazi; N A N Kumar; J Rohila; V Sukumar; R Engineer; S Ankathi; A Desouza; A Saklani
Journal:  BJS Open       Date:  2021-09-06

2.  Perioperative management and anaesthetic considerations in pelvic exenterations using Delphi methodology: results from the PelvEx Collaborative.

Authors: 
Journal:  BJS Open       Date:  2021-01-08

3.  Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach.

Authors:  Tetsuro Tominaga; Takashi Nonaka; Akiko Fukuda; Toshio Shiraisi; Shintaro Hashimoto; Masato Araki; Yorihisa Sumida; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Ann Surg Treat Res       Date:  2021-07-29       Impact factor: 1.859

Review 4.  Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative.

Authors: 
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.575

5.  Robotic Pelvic Exenteration for Gynecologic Malignancies, Anatomic Landmarks, and Surgical Steps: A Systematic Review.

Authors:  Stefano Cianci; Martina Arcieri; Giuseppe Vizzielli; Canio Martinelli; Roberta Granese; Marco La Verde; Anna Fagotti; Francesco Fanfani; Giovanni Scambia; Alfredo Ercoli
Journal:  Front Surg       Date:  2021-11-30

6.  Opportunities and Limitations of Pelvic Exenteration Surgery.

Authors:  Björn Lampe; Verónica Luengas-Würzinger; Jürgen Weitz; Stephan Roth; Friederike Rawert; Esther Schuler; Sabrina Classen-von Spee; Nando Fix; Saher Baransi; Anca Dizdar; Peter Mallmann; Klaus-Dieter Schaser; Andreas Bogner
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.